Companies › Vir Biotechnology
6 active drug programs in 11 registered trials: 5 Phase 2, 4 Phase 3, 2 Phase 1; Infectious disease, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Elebsiran Apolipoprotein B (APOB) antisense oligonucleotide inhibitor | APOB | Phase 3 | Viral Hepatitis | Nov 2026 |
| Tobevibart AAV receptor antagonist | AAVR | Phase 3 | Viral Hepatitis | Nov 2026 |
| VIR-2218 HDV biosynthesis inhibitor; targets delta antigen | – | Phase 2 | Hepatitis D, Chronic | Nov 2031 |
| VIR-3434 Hepatitis B virus surface antigen (HBsAg) inhibitor | – | Phase 2 | Hepatitis D, Chronic; Hepatitis B, Chronic | Nov 2031 |
| VIR-5818 HER2-targeting immunotherapy (bispecific antibody engaging HER2 and immune effector cells) | – | Phase 1 | Locally Advanced or Metastatic HER2-Expressing Cancers | Apr 2028 |
| VIR-5525 EGFR-targeting immunotherapy | EGFR | Phase 1 | Solid Tumor Malignancies | Aug 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07142811 | Tobevibart | Phase 2 | Viral Hepatitis | Infectious disease | Nov 2026 |
| NCT07142811 | Elebsiran | Phase 2 | Viral Hepatitis | Infectious disease | Nov 2026 |
| NCT07128550 | Tobevibart | Phase 3 | Viral Hepatitis | Infectious disease | Dec 2026 |
| NCT07128550 | Elebsiran | Phase 3 | Viral Hepatitis | Infectious disease | Dec 2026 |
| NCT05356741 | VIR-5818 | Phase 1 | Locally Advanced or Metastatic HER2-Expressing Cancers | Oncology | Apr 2028 |
| NCT06960395 | VIR-5525 | Phase 1 | Solid Tumor Malignancies | Oncology | Aug 2029 |
| NCT06216470 | VIR-3434 | Phase 2 | Hepatitis B, Chronic | Infectious disease | Dec 2029 |
| NCT06903338 | Tobevibart | Phase 3 | Viral Hepatitis | Infectious disease | May 2031 |
| NCT06903338 | Elebsiran | Phase 3 | Viral Hepatitis | Infectious disease | May 2031 |
| NCT05461170 | VIR-2218 | Phase 2 | Hepatitis D, Chronic | Infectious disease | Nov 2031 |
| NCT05461170 | VIR-3434 | Phase 2 | Hepatitis D, Chronic | Infectious disease | Nov 2031 |
Cash and short-term investments of $455m on 2026-09-30; operating cash outflow about $155m a year; runway about 35 months at that burn, to Sep 2029; 2 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Serum Institute of India Suzhou Abogen Biosciences Sanaria Eveliqure Biotechnologies Brii Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.